FDA Approves INREBIC — Celgene Corporation

# FDA Approves Celgene's INREBIC (Fedratinib) for Myelofibrosis Treatment Celgene Corporation has received FDA approval for INREBIC (fedratinib hydrochloride), an oral JAK2 inhibitor for myelofibrosis, expanding the company's oncology portfolio and positioning it to compete in the growing market for myeloproliferative neoplasm therapies alongside existing players like Incyte and Acceleron Pharma.